Meeting Demand for Biologics: The Bioprocessing Summit Explores Today’s Challenges and Tomorrow’s Advances

From Digital Biomanufacturing to mAb Production, Keynoters to Share
Insights During August 12-16, 2019 Conference in Boston

BOSTON–(BUSINESS WIRE)–#BPSMT–To meet exploding demand for biological drugs that can cure fatal
diseases, counter chemical threats, or fight cancer, the bioprocessing
industry is evolving to “digital biomanufacturing”— capitalizing on
innovations like predictive analytics to fast track their protein-based
therapies.

From August 12-16, 2019, more than 1,500 scientists, engineers and
leaders from this international community will unite at The
Bioprocessing Summit in Boston to explore the transformation ahead. They
will also share new solutions to the challenges they encounter today, as
they work to maximize quality, safety and cost-efficiency in the
biologics manufacturing process.

“Distinguished by its high-caliber scientific content, the eleventh
annual Bioprocessing Summit will offer abundant opportunities to access
new data, case studies, technologies and techniques, and initiate
valuable collaborations,” said Mary Ruberry, Senior Conference Director,
Cambridge Healthtech Institute, which produces this event.

This year’s Plenary
Keynote Sessions will focus on current challenges and future
innovations:

Leading to Tomorrow’s Advances (August 12)

• Biologic Therapies in the Coming Decade: Modalities and Development
  Strategies, with Yatin Gokarn, PhD, Vice President, Global Head,
  Biologics Drug Product Development, Sanofi Pharmaceuticals
• The Future of Bioprocessing – A Digital Era Awaits, with Anthony
  Mire-Sluis, PhD, Head, Global Quality, AstraZeneca Pharmaceuticals
• Session Chairperson Sue Behrens, PhD, Senior Director, Process Design,
  IPS, will kick off the program

Solving Today’s Challenges (August 14)

• Evolving Trends in mAb Production Processes, with Sanchayita Ghose,
  PhD, Director, Biologics Process Development, Bristol-Myers Squibb Co.
• Today’s Challenges and Opportunities in Biomanufacturing, with Judy
  Chou, PhD, Senior Vice President and Global Head, Biotech, Bayer
  Pharmaceuticals
• Session Chairperson John Sterling, Editor, Genetic Engineering &
  Biotechnology News, will open the discussions

The Bioprocessing Summit will include 200+
presentations on upstream and downstream processing, analytical and
quality, formulation and stability, cell and gene therapy,
manufacturing, and more.

In addition to one-on-one networking, an Exhibit Hall with 110+
cutting-edge innovators, and 80+ poster
sessions, the conference will feature training
seminars, special
events sponsored by the International Society for Cell and Gene
Therapy (ISCT), Women in Bio (WIB) and The National Institute for
Innovation in Manufacturing Biopharmaceuticals (NIIMBL), breakout
discussions and short
courses.

Please see bioprocessingsummit.com.

About Cambridge Healthtech Institute

Cambridge
Healthtech Institute (CHI), a division of Cambridge Innovation
Institute, is the preeminent life science network for leading
researchers and business experts from top pharmaceutical, biotech, CROs,
academia, and niche service providers. CHI is renowned for its vast
conference portfolio held worldwide including PepTalk, Molecular
Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo,
PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World
Preclinical Congress, The Bioprocessing Summit, Next Generation Dx
Summit, Immuno-Oncology Summit, and Discovery on Target. CHI’s portfolio
of products include Cambridge Healthtech Institute Conferences, Barnett
International, Insight Pharma Reports, Bio-IT World, Clinical
Research News and Diagnostics World.

Contacts

Dawn Ringel
781-449-8456
[email protected]